BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 37688519)

  • 1. Molecular and environmental contributors to neurological complications in sickle cell disease.
    Karkoska KA; Gollamudi J; Hyacinth HI
    Exp Biol Med (Maywood); 2023 Aug; 248(15):1319-1332. PubMed ID: 37688519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
    Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
    Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Doree C; Abboud MR
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012389. PubMed ID: 28500860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Estcourt LJ; Kohli R; Hopewell S; Trivella M; Wang WC
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003146. PubMed ID: 32716555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Wang WC
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD003146. PubMed ID: 28094851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
    Fortin PM; Hopewell S; Estcourt LJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Wang WC; Dwan K
    Cochrane Database Syst Rev; 2013 Nov; (11):CD003146. PubMed ID: 24226646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stroke in sickle cell disease and the promise of recent disease modifying agents.
    Runge A; Brazel D; Pakbaz Z
    J Neurol Sci; 2022 Nov; 442():120412. PubMed ID: 36150233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea can be used in children with sickle cell disease and cerebral vasculopathy for the prevention of chronic complications? A meta-analysis.
    Núñez RM; Figueroa CAP; García-Perdomo HA
    J Child Health Care; 2020 Mar; 24(1):64-77. PubMed ID: 30606035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sickle Cell Disease: A Review.
    Kavanagh PL; Fasipe TA; Wun T
    JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
    Rankine-Mullings AE; Nevitt SJ
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD002202. PubMed ID: 36047926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
    Nevitt SJ; Jones AP; Howard J
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative blood transfusions for sickle cell disease.
    Estcourt LJ; Kimber C; Trivella M; Doree C; Hopewell S
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003149. PubMed ID: 32614473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea for children with sickle cell disease in sub-Saharan Africa: A summary of the evidence, opportunities, and challenges.
    Dexter D; McGann PT
    Pharmacotherapy; 2023 May; 43(5):430-441. PubMed ID: 36906823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-Modifying Therapies for Sickle Cell Disease-An Overview.
    Peddinti R
    Pediatr Ann; 2024 Feb; 53(2):e52-e55. PubMed ID: 38302121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current challenges in the management of patients with sickle cell disease - A report of the Italian experience.
    Russo G; De Franceschi L; Colombatti R; Rigano P; Perrotta S; Voi V; Palazzi G; Fidone C; Quota A; Graziadei G; Pietrangelo A; Pinto V; Ruffo GB; Sorrentino F; Venturelli D; Casale M; Ferrara F; Sainati L; Cappellini MD; Piga A; Maggio A; Forni GL
    Orphanet J Rare Dis; 2019 May; 14(1):120. PubMed ID: 31146777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
    Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
    JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sickle Cell Disease and Stroke.
    Hirtz D; Kirkham FJ
    Pediatr Neurol; 2019 Jun; 95():34-41. PubMed ID: 30948147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood transfusion for preventing stroke in people with sickle cell disease.
    Riddington C; Wang W
    Cochrane Database Syst Rev; 2002; (1):CD003146. PubMed ID: 11869654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.